🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: HFO MDI

Found 11 matching trials

A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer

PHASE1

The primary purpose of this study is to demonstrate the equivalence of bude...

Status

Withdrawn

Location

Multiple Locations

Start Date

2024-10-17

Trial ID

NCT06340581

Treatments Being Tested

Treatment A: BGF MDI HFA Treatment B: BGF MDI HFO Treatment C: BGF MDI HFO AeroChamber Plus Flow-Vu Spacer

Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.

PHASE1

This study will investigate the Pharmacokinetic (PK) and safety of Budesoni...

Status

Completed

Location

Research Site

Start Date

2023-11-16

Trial ID

NCT06139991

Treatments Being Tested

Treatment A (BDA MDI HFO)Treatment B (BDA MDI HFA)

A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

PHASE3

This is a 12-week (with an extension to 52 weeks in a subset of participant...

Status

Completed

Location

Research Site

Start Date

2022-09-27

Trial ID

NCT05573464

Treatments Being Tested

BGF MDI HFO 320/14.4/9.6 μg BGF MDI HFA 320/14.4/9.6 μg

Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma

PHASE3

A study to assess bronchospasm potentially induced by HFO MDI as compared w...

Status

Completed

Location

Research Site

Start Date

2023-05-02

Trial ID

NCT05850494

Treatments Being Tested

HFA MDI HFO MDI

Study to Assess Effect of Next-Generation Propellant MDI on Mucociliary Clearance Vs. HFA Propellant MDI in Healthy Participants

PHASE3

A Study to Assess the Effect of the HFO MDI Propellant on Mucociliary Clear...

Status

Completed

Location

Research Site

Start Date

2023-06-14

Trial ID

NCT05755932

Treatments Being Tested

HFO-1234ze(E)HFA-134a

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD

PHASE3

The purpose of this study is to demonstrate that the lung function effect f...

Status

Completed

Location

Research Site

Start Date

2024-01-11

Trial ID

NCT06075095

Treatments Being Tested

BGF MDI HFO 320/14.4/9.6μg BGF MDI HFA 320/14.4/9.6 μg Placebo MDI HFA

A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

PHASE3

The purpose of this study is to assess the PD equivalence of the approved a...

Status

Active Not Recruiting

Location

Research Site

Start Date

2024-07-22

Trial ID

NCT06502366

Treatments Being Tested

BDA MDI HFO 160/180 μg BDA MDI HFA 160/180 μg Placebo MDI HFA

A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer

PHASE1

This study aims to assess the effect on total systemic exposure and to char...

Status

Completed

Location

Research Site

Start Date

2024-04-29

Trial ID

NCT06297668

Treatments Being Tested

Treatment A: BGF MDI HFA Treatment B: BGF MDI HFO Treatment C: BGF MDI HFO AeroChamber Plus Flow-Vu spacer

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

PHASE1

The study will assess the Pharmacokinetic (PK) and safety of BGF MDI \[Bude...

Status

Completed

Location

Research Site

Start Date

2022-07-29

Trial ID

NCT05477108

Treatments Being Tested

Treatment A (BGF MDI HFO with oral activated charcoal)Treatment B (BGF MDI HFA with oral activated charcoal)

A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults

PHASE1

This study aims to assess the bioequivalence of the total systemic exposure...

Status

Completed

Location

Research Site

Start Date

2025-01-23

Trial ID

NCT06723756

Treatments Being Tested

Treatment A: BGF MDI HFO Treatment B: BGF MDI HFA

Previous Next